6-乙基-5-甲基-2(1H)-吡啶酮 | 99307-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-乙基-5-甲基-2(1H)-吡啶酮
• 英文名称: 6-ethyl-5-methyl-pyridin-2-ol
• 英文别名: 6-Aethyl-5-methyl-pyridin-2-ol；6-ethyl-5-methyl-1H-pyridin-2-one
• CAS: 99307-96-7
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: VWBCYWNXJXZABS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-乙基-5-甲基-2(1H)-吡啶酮 在 镍 盐酸 、 manganese(IV) oxide 、 正丁基锂 、 四甲基乙二胺 、 硫酸 、 苄基三乙基氯化铵 、 氢气 、 硝酸 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 80.0 ℃ 、202.65 kPa 条件下， 反应 28.0h， 生成 3-amino-6-ethyl-5-methyl-4-(3-methylbenzoyl)-1H-pyridin-2-one
  参考文献：
  名称：

  4-Benzyl and 4-Benzoyl-3-dimethylaminopyridin-2(1H)-ones:  In Vitro Evaluation of New C-3-Amino-Substituted and C-5,6-Alkyl-Substituted Analogues against Clinically Important HIV Mutant Strains

  摘要：

  In a program to optimize the anti-HIV activity of the 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 9 and 10, lead compounds in a new class of highly potent non-nucleoside type inhibitors of HIV-1 reverse transcriptase, modification of the alkyl substitutents at the C-5 and C-6 positions on the pyridinone ring and of the substitutents on the C-3 amino group has been studied. Of the 17 new 5/6-modified analogues prepared, compounds 31b and 32b substituted at C-5 by an extended nonpolar chain containing an ether function and a C-6 methyl group and compound 35 bearing a C-5 ethyl/C-6 hydroxymethyl substituent pattern were selected on the basis of their in vitro activity against wild-type HIV and the three principle mutant strains, K103N, Y181C, and Y188L. When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L1001 + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A] which are clinically relevant. Concerning modulation of the N-3 substituent, 36 new analogues were prepared. Of these, the N-methyl-N-(2-methoxyethyl)-substituted compounds 40, 42, and 62, as well as the doubly modified compounds 77a and 77b, were selected from the initial screen and were subsequently shown to be active at sub-micromolar concentrations (IC50'S) against all the other mutant strains except K103N + Y181C and F227L + V106A. Two possible, but distinct, modes of binding of these analogues in RT were suggested from molecular modeling studies. The preferred mode of binding for compound 62, corresponding to the predicted "orientation 1", was revealed in the X-ray crystal structure of the compound 62-RT complex.

  DOI：

  10.1021/jm0408621
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 6-乙基-5-甲基-2(1H)-吡啶酮
  参考文献：
  名称：

  Sen-Gupta, Journal of the Chemical Society, 1915, vol. 107, p. 1363

  摘要：

  DOI：

文献信息

• Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists
  申请人：Chackalamannil Samuel

  公开号：US20080090830A1

  公开（公告）日：2008-04-17

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  具有以下结构的杂环取代的三环化合物，或者该化合物的药用盐或溶剂化合物、异构体或消旋混合物，其中表示一个可选的双键，虚线可以是一个键或无键，从而形成一个双键或一个单键，符合化合价要求，E、A、G、M、Het、B、X、R3、R10、R11、R32和R33在此有定义，其余取代基如规范中所定义，以及含有它们的药物组合物和通过给予该化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声称与其他心血管药物的联合疗法。
• COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
  申请人：Azimioara Mihai

  公开号：US20110190263A1

  公开（公告）日：2011-08-04

  The invention provides compounds of Formula (I): pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

  该发明提供了式（I）的化合物：包括这些化合物的药物组合物以及使用这些化合物治疗或预防与GPR119活性相关的疾病或障碍的方法。
• Pessolano, A. A.; Witzel, B. E.; Graham, P. M., Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 265 - 272
  作者：Pessolano, A. A.、Witzel, B. E.、Graham, P. M.、Clark, R. L.、Jones, H.、at al.

  DOI：——

  日期：——
• PESSOLANO, A. A.;WITZEL, B. E.;GRAHAM, P. M.;CLARK, R. L.;JONES, H.;DORN,+, J. HETEROCYCL. CHEM., 1985, 22, N 2, 265-272
  作者：PESSOLANO, A. A.、WITZEL, B. E.、GRAHAM, P. M.、CLARK, R. L.、JONES, H.、DORN,+

  DOI：——

  日期：——
• BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS
  申请人：Chackalamannil Samuel

  公开号：US20120157403A1

  公开（公告）日：2012-06-21

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.